Kiora Pharmaceuticals, Inc. Common Stock (KPRX)

Price$2.50

Value ScoreA

Growth ScoreA

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)18.34%

Price vs S&P 500 (4W)2.05%

VGM Score80.30

Market Capitalization$11.08M

P/E Ratio (Annual)2.73x

All Metrics

P/CF (Annual)1.14x

Book Value / Share (Quarterly)$3.49

P/TBV (Annual)0.52x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)81.26%

Cash Flow / Share (Quarterly)$-2.64

Price vs S&P 500 (YTD)18.75%

Net Profit Margin (TTM)70.11%

EPS (TTM)$-2.62

10-Day Avg Trading Volume0.03M

EPS Excl Extra (TTM)$-2.62

Revenue Growth (5Y)108.15%

EPS (Annual)$-2.60

ROI (Annual)-67.19%

Net Profit Margin (5Y Avg)-17004.21%

Cash / Share (Quarterly)$3.47

P/E Normalized (Annual)2.73x

ROA (Last FY)-44.67%

EBITD / Share (TTM)$-3.06

ROE (5Y Avg)-94.30%

Operating Margin (TTM)66.65%

Cash Flow / Share (Annual)$-2.68

P/B Ratio0.80x

P/B Ratio (Quarterly)0.55x

Net Income / Employee (Annual)$-833,500

Net Interest Coverage (TTM)-8.86x

ROA (TTM)-36.09%

EV / EBITDA (TTM)0.03x

EPS Incl Extra (Annual)$-2.60

Current Ratio (Annual)5.99x

Quick Ratio (Quarterly)6.19x

3-Month Avg Trading Volume0.36M

52-Week Price Return-19.09%

EV / Free Cash Flow (Annual)0.50x

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$2.97

P/S Ratio (Annual)0.69x

Asset Turnover (Annual)0.44x

52-Week High$3.39

Operating Margin (5Y Avg)-17089.00%

EPS Excl Extra (Annual)$-2.60

CapEx CAGR (5Y)40.83%

26-Week Price Return26.26%

Quick Ratio (Annual)5.62x

13-Week Price Return23.15%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.68x

Enterprise Value$124,500

Revenue / Share Growth (5Y)-28.30%

Asset Turnover (TTM)0.38x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)35.33%

Cash / Share (Annual)$4.54

3-Month Return Std Dev84.59%

Net Income / Employee (TTM)$-833,500

ROE (Last FY)-67.19%

Net Interest Coverage (Annual)-2.61x

EPS Basic Excl Extra (Annual)$-2.60

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.62

ROI (TTM)-51.37%

P/S Ratio (TTM)0.69x

Pretax Margin (5Y Avg)-17045.28%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$3.74

Price vs S&P 500 (52W)-43.46%

Year-to-Date Return26.90%

5-Day Price Return-10.87%

EPS Normalized (Annual)$-2.60

ROA (5Y Avg)-53.44%

Net Profit Margin (Annual)22.44%

Month-to-Date Return-6.72%

Cash Flow / Share (TTM)$-6.49

EBITD / Share (Annual)$-3.07

Operating Margin (Annual)27.50%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-94.30%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.62

P/TBV (Quarterly)0.64x

P/B Ratio (Annual)0.45x

Pretax Margin (TTM)70.11%

Book Value / Share (Annual)$4.29

Price vs S&P 500 (13W)14.90%

Beta-0.36x

P/FCF (Annual)1.30x

Revenue / Share (TTM)$0.00

ROE (TTM)-51.37%

52-Week Low$1.76

vGradeA

gGradeA

mGradeC

vgmGradeA

Show chart for

Earnings Surprise History

Q1 26-0.58est. -0.72

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.14

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
KPRXKiora Pharmaceuticals, Inc. Common Stock	A	A	C	$2.50
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Kiora Pharmaceuticals is a clinical-stage biotechnology company developing therapies for rare retinal diseases. Its lead program, KIO-301, is a molecular photoswitch designed to restore vision in inherited retinal degenerative diseases including retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also advancing KIO-104, a non-steroidal immunomodulator for posterior non-infectious uveitis.